Danaher Corporation announced that the Company's Board of Directors has appointed Julie Sawyer Montgomery as President and Chief Executive Officer and a member of the Board of Directors, effective October 1, 2026. "In alignment with the Board of Directors' succession planning process, I am pleased to announce the ap…
TriNetX, The Global Truth Engine for Better Human Health and operator of the world's leading federated health data network, announced the appointment of August Calhoun as Chief Executive Officer, effective immediately. Jeff Margolis, who has led the Company as the Interim CEO and Executive Chairman since December 2024…
Tessera Therapeutics, the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing, announced the appointment of Joseph Romanelli as President and Chief Executive Officer. Romanelli succeeds Michael Severino who has led the company since June 2022. Romanelli will join Tessera's board o…
Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, announced a planned leadership transition as Ascidian heads into the next chapter. Michael Ehlers, M.D., Ph.D., has stepped down as President and Chief Executive Officer and will continue to serve as Chair of the Board of…
Roche announced the appointment of Dan Malarek as President and CEO of Roche Diagnostics North America, effective August 1, 2026. Malarek currently serves as Chief Executive Officer of Foundation Medicine Inc., an independent affiliate of the Roche Group. Malarek succeeds Brad Moore, who will retire at the end of July…
LumaCina, a global supplier and marketer of sterile injectable pharmaceutical products and a Bridgewest Group portfolio company, announced the appointment of Gary Bird as Chief Executive Officer. Bird was appointed by Executive Chair Mark Crotty, who will continue to lead LumaCina's long-term strategy, overseeing the…
Cellular Intelligence, the AI company building a universal foundation model of cell signaling, announced the addition of two senior leaders to its executive team, as it prepares for the next phase of growth. Jonathan Alspaugh, chief strategy officer, joins with over 15 years of experience in biopharma strategy, financ…
DePuy Synthes, a global leader in orthopaedic technologies and solutions, announced the appointment of Christina Zamarro as Chief Financial Officer, DePuy Synthes, effective July 13, 2026. Zamarro brings over 25 years of financial leadership experience serving in multitude of roles across treasury, investor relations…
Syngene International, a global contract research, development, and manufacturing organization (CRDMO), announced that Siddharth Mittal has assumed the role of Managing Director and Chief Executive Officer of the Company, effective 1 July 2026.Siddharth succeeds Peter Bains, who completed his tenure as Managing Direct…
Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced the appointment of Torsten Woehr as Chief Executive Officer (CEO), effective August 1, 2026. Torsten Woehr, incoming CEO of Rentschler Biopharma, commented: “Rentschler Biopharma is r…
Page 1 of 14